Gartin v. Par Pharmaceutical Co.

289 F. App'x 688
CourtCourt of Appeals for the Fifth Circuit
DecidedJuly 24, 2008
Docket07-40451
StatusUnpublished
Cited by76 cases

This text of 289 F. App'x 688 (Gartin v. Par Pharmaceutical Co.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Fifth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Gartin v. Par Pharmaceutical Co., 289 F. App'x 688 (5th Cir. 2008).

Opinion

PER CURIAM: *

Spencer and Donna Gartin appeal the district court’s grant of Par Pharmaceutical, Inc.’s motion to quash summons and return of service and the dismissal of their claims against this defendant. We review the district court’s dismissal for an abuse of discretion. Finding none, we affirm.

*690 I. FACTS AND PROCEDURAL BACKGROUND

The backdrop for the procedural issues that now confront this court is the tragic death of the Gartins’ fifteen year old daughter, Sabrina. In November 2004, Sabrina Gartin was prescribed fluoxetine, a generic form of the antidepressant drug Prozac. Four months later, on March 28, 2004, Sabrina Gartin committed suicide.

On March 27, 2006, one day before the relevant Texas statute of limitations expired, the Gartins filed a wrongful death suit in the United States District Court for the Eastern District of Texas and named the Defendant(s) this way: “Par Pharmaceutical Companies, Inc., a Delaware corporation, a/k/a and/or d/b/a Par Pharmaceutical, Inc., and/or as Pharmaceutical Resources, Inc., foreign corporations, Black and White Corporations IV and Black and White Corporations I-V, Defendants.” The Gartins alleged that Sabrina’s suicide was caused by her use of fluoxetine, which they claimed was “manufactured and marketed by the Defendants.” On April 18, 2006, the Gartins’ counsel, Andy Vickery, mailed a Notice of Lawsuit and Request for Waiver of Service of Summons to “Defendants, Par Pharmaceutical Companies, Inc., a Delaware corporation, a/k/a and/or d/b/a Par Pharmaceutical, Inc., and/or as Pharmaceutical Resources, Inc., foreign corporations, by and through their attorney of record, Joseph P. Thomas, Esq.” On June 21, 2006, having received no response from the entities listed in the notice and waiver, Vickery asked counsel for Par (Joseph Thomas) whether the waiver would be returned. He was informed that Par “declined to sign the notice.”

On June 28, 2006, the district court issued a “Notice of Impending Dismissal,” informing the parties that, although ninety days had passed since the filing of the Gartins’ complaint, none of the defendants had been served in accordance with Federal Rule of Civil Procedure 4. The notice reiterated that under Rule 4(m) service of process must be completed within 120 days of filing a complaint. The Notice also advised the Gartins that, if more than 120 days would be needed to serve any of the defendants, their counsel must request an extension from the court on or before July 25, 2006 (the expiration of the 120-day service deadline). If dismissal of the case as to any unserved defendant was agreeable, the Gartins were not required to act. 1

On June 30, 2006, pursuant to the Gar-tins’ request, the clerk of the court issued a summons to:

Par Pharmaceuticals Companies, Inc., a Delaware corporation, a/k/a and/or d/b/a Par Pharmaceutical, Inc. and/or as Pharmaceutical Resources, Inc., c/o its Registered Agent, Corporation Service Company, 2711 Centerville Road, Suite 400, Wilmington, New Castle County, Delaware, 19808.

The Gartins’ attorney sent the summons and a copy of the complaint via certified mail in an envelope addressed to “Par Pharmaceutical Companies Inc.” in care of its registered agent. The attorney later filed a return of service indicating that Par Pharinaceutical Companies, Inc. had been served on July 10, 2006.

On July 31, 2006, Par Pharmaceutical Companies, Inc. filed a motion to dismiss for lack of personal jurisdiction and insufficiency of service of process. No other Par entity responded to the summons. Par Pharmaceutical Companies, Inc. asserted that it neither marketed nor manufactured fluoxetine in Texas and therefore was im *691 properly served. The Gartins responded to the motion by arguing that jurisdiction over Par Pharmaceutical Companies, Inc. was proper because it was one and the same with Par Pharmaceutical, Inc., its wholly-owned subsidiary. Alternatively, the Gartins argued that they had sued all Par entities, but were willing to dismiss Par Pharmaceutical Companies, Inc. if Par Pharmaceutical, Inc. remained in the suit and the court permitted the Gartins to effectuate service on them.

A case management conference was held on October 20, 2006, during which the parties discussed whether the Par entities were one and the same for purposes of the Gartins’ suit and whether both entities had been sued. The district court indicated that it would not issue a ruling on the motion to dismiss until sometime in November. Shortly after the conference, on October 28, 2006, the Gartins’ attorney procured a summons to “Par Pharmaceutical, Inc.” in care of its registered agent, Corporation Service Company (the same agent appointed by Par Pharmaceutical Companies, Inc.). Par Pharmaceutical, Inc. was served on October 25, 2006, and subsequently filed a motion to quash summons and return of service and to dismiss the complaint pursuant to Federal Rule of Civil Procedure 12(b)(4), relating to insufficiency of process, and Rule 12(b)(5), relating to insufficiency of service of process. The Gartins responded by filing a motion to extend the time for service.

The district court first granted Par Pharmaceutical Companies, Inc.’s motion to dismiss for lack of personal jurisdiction. The district court then granted Par Pharmaceutical, Inc.’s motion, quashing the summons and return of service and dismissing without prejudice all claims against it. In so doing, the district court acknowledged that the two-year statute of limitations “may have run,” thus barring a subsequent suit by the Gartins. See Tex. Civ. Prac. & Rem.Code Ann. § 16.003 (Vernon 2005). The district court found that Plaintiffs failed to name Par Pharmaceutical, Inc. as a defendant. Alternatively, the district court found that even if Par Pharmaceutical, Inc. was a named defendant, the court would not permit the Gar-tins an extension of time for service because they could not demonstrate “good cause” for their failure to serve within 120 days.

The Gartins appealed only the grant of Par Pharmaceutical, Inc.’s motion, arguing that the district court erred in granting the motion to quash service and return of service and dismissing their claims against Par Pharmaceutical, Inc. 2

II. DISCUSSION

As noted above, Par Pharmaceutical, Inc. moved to dismiss the Gartins’ suit under both Rule 12(b)(4) and Rule 12(b)(5). The district court cited both rules as authority for granting Par Pharmaceutical, Inc.’s motion to dismiss. 3 We *692 review an order quashing service and granting dismissal for failure to effect timely service of process for an abuse of discretion. Lindsey v. United States R.R. Ret. Bd., 101 F.3d 444

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
289 F. App'x 688, Counsel Stack Legal Research, https://law.counselstack.com/opinion/gartin-v-par-pharmaceutical-co-ca5-2008.